Saracatinib s1006

The library of FDA-approved drugs (Screen-Well FDA-Approved Drug Library, 640 chemical compounds dissolved at 10 mM in dimethylsulphoxide (DMSO)) was obtained from Enzo Life Sciences (Enzo Life Sciences Inc.,Plymouth Meeting, PA, USA).
The following compounds were purchased from Sigma Aldrich: HC (H0888), verteporfin (SML0534), PX (T7191), RU486 (Mifepristone; M8046), BM (B7005), PF573228 (PZ0117). RGD is fibronectin tetrapeptide (H-Arg-Gly-Asp-Ser-OH) from Santa Cruz (sc-202156).
Latrunculin A (sc-202691) was from Sigma, saracatinib (S1006) and dasatinib (S1021) from Selleck.
8XGTII-Luc and the retroviral construct coding for Flag-YAP-5SA were previously described16 (link). Lentiviral constructs coding for short hairpin NR3C1 (GR) was from Sigma (Clone ID:NM_000176.2-6190s21c1).

Recombinant human RSPO2 protein (3266-rs-025/cf) and Wnt3a (5036-WN-500) was purchased from R&D Systems (USA). The FAK inhibitor defactinib (1073154-85-4) was purchased from RayStar Biosystems (China). The Src inhibitor saracatinib (S1006) and Akt inhibitor LY294002 (S1105) were purchased from Selleck (China). The Frizzled inhibitor Niclosamide was purchased from Sigma-Aldrich (St. Louis, MO). Cycloheximide(CHX) was purchased from Sigma (C7698). SiRNAs targeting the open reading frames of RSPO2, LGR4, ITGAV, and ITGB3 were synthesized by GenePharma (Shanghai, China). Lentivirus containing shRNA against RSPO2 was designed and produced by GeneChem Co. (Shanghai, China), siRNA and shRNA sequences are listed in Table S1. Cells grown to a confluence of 50–70% were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions and plated again for further experiments. The knockdown efficiency was determined using qRT-PCR or western blotting. All antibodies were purchased from commercial manufacturers, and detailed information is listed inTable S2.